Ottawa, ON — November 30, 2017 — Avivagen Inc. (TSXV:VIV) (OTC Pink:CHEXF) (“Avivagen” or the “Company”), a life sciences innovation company with a series of patent protected products that support and optimize human and animal health, is pleased to announce the successful completion of a private placement financing (the “Offering”), issuing 2,913,500 units (the “Units”) at an issue price of $1.00 (the “Offering Price”) per Unit for aggregate gross proceeds to the Company of $2,913,500. The Offering was completed by a syndicate of agents led by Beacon Securities Limited as lead agent and including Bloom Burton & Co., Dominick Capital Corporation and Industrial Alliance Securities Inc. (collectively, the “Agents”).

Read the full press release here.